Effectiveness of a triple inhaler for COPD in Brazil
Part of Lungs & breathing clinical trials.
This study looks at how well a triple inhaler (BDP/FF/GB) works for people with severe COPD in Brazil. It may help those who have had at least one flare-up in the past year.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 40 years or older when starting the triple inhaler.
- You have severe or very severe COPD diagnosed before starting the inhaler.
- Your COPD symptoms (CAT score) were at least 10 when starting the inhaler or within the year before.
- You have had at least 1 COPD flare-up (exacerbation) in the last 12 months before joining.
- You started the triple inhaler within 3 months before signing up, or on the day you sign up.
- You are not taking part in any other research study during the 3 months before starting the inhaler or during this study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people with severe or very severe COPD to learn more about their health over time. You may qualify if your COPD causes many symptoms or frequent flare-ups.
This study looks at the health of Brazilian adults with COPD. It aims to understand how the condition affects people and may help improve future treatments.
This study tests a triple-combination inhaler (budesonide, glycopyrronium, and formoterol) to see if it can help protect the heart and lungs in people with COPD who also have heart problems or high risk for them.
This trial looks at how long-term health conditions like heart disease, diabetes, or high blood pressure might affect breathing problems. The goal is to better understand and help people with both issues.
This trial tests a new inhaler that combines three medicines (fluticasone, formoterol, and glycopyrronium) to see if it helps people with chronic obstructive pulmonary disease (COPD) breathe better and have fewer flare-ups. It may be an option if you have COPD and are looking for a convenient once- or twice-daily treatment.
This study tests a fixed triple combination inhaler (Trimbow) for people whose asthma is not well controlled with their current treatment. It looks at how well this inhaler works in everyday life over time.
Hear when a new COPD (Chronic Obstructive Pulmonary Disease) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.